Another Adalimumab Biosimilar Seems Set for Interchangeability

(MedPage Today) -- PHILADELPHIA--Pfizer has made the case for gaining the coveted "interchangeability" status for its adalimumab biosimilar (Abrilada), a study presented here suggested.
A pivotal trial involving nearly 445 rheumatoid arthritis...